Mira Pharmaceuticals Inc
MIRA
Company Profile
Business description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Contact
1200 Brickell Avenue
Suite 1950 No. 1183
MiamiFL33133
USAT: +1 786 432-9792
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Amazon earnings: Guidance for $200 billion in capital expenditure in 2026 overshadows good results
We think Amazon stock is moderately undervalued.
stocks
Apple earnings: Impressive Q4 lifts stock, but is it a long-term growth play?
We’ve raised our fair value estimate of Apple stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,131.10 | 65.20 | 0.72% |
| CAC 40 | 8,283.42 | 9.58 | 0.12% |
| DAX 40 | 24,817.47 | 96.01 | 0.39% |
| Dow JONES (US) | 49,683.57 | 182.27 | 0.37% |
| FTSE 100 | 10,362.01 | 7.74 | -0.07% |
| HKSE | 27,027.16 | 467.21 | 1.76% |
| NASDAQ | 23,031.21 | 126.63 | 0.55% |
| Nikkei 225 | 56,363.94 | 2,110.26 | 3.89% |
| NZX 50 Index | 13,446.37 | 2.35 | 0.02% |
| S&P 500 | 6,861.29 | 62.89 | 0.93% |
| S&P/ASX 200 | 8,870.10 | 59.20 | 0.67% |
| SSE Composite Index | 4,123.09 | 57.51 | 1.41% |